Orthobiologics Market Size, Trends and Forecast to 2030

Orthobiologics use body’s own cells and healing factors to reverse the effects of orthoarthritis and accelerate healing of tendon and ligament injuries (rotator cuff tendonitis, ankle sprain, etc). Orthobiologics involve substances that help the body to heal more quickly. They can improve the healing of injured muscles, tendons, and ligaments and help to repair damage from osteoarthritis. These products are made from substances that are naturally found in body. Stem cells are special cells in body that can turn into other types of cells. During the healing process, stem cells are called to the area of body that needs to repair.

The global orthobiologics market is estimated to be valued at US$ 6,515.2 million in 2022 and is expected to exhibit a CAGR of 5.9% during the forecast period (2022-2030).

Figure 1. Global Orthobiologics Market Share (%), by Product Type, 2022

Global Orthobiologics Market - Drivers

Adoption of inorganic growth strategies such as product launches by key market players is expected to drive the global orthobiologics market growth over the forecast period. For instance, in July 2022, Ossifix Orthopedics, a subsidiary of Umbra Applied Technologies Group, Inc., announced that they had launched crunch, a demineralized bone matrix that contains cancellous bone fragments to provide the osteoconductive scaffolding to promote new bone growth. This product launch will expand its suite of orthopedic products.

Orthobiologics Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 6,515.2 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	5.9%	2030 Value Projection:	US$ 10,300.6 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Product Type: Bone Allograft, Machined Bones, Demineralized Bone Matrix, Synthetic Bone Substitutes, Bone Morphogenetic Protein (BMP), Stem Cell Therapy, Viscosupplementation By Application: Spinal Fusion, Trauma, Reconstructive Surgeries By End User: Hospitals, Ambulatory Surgical Centers, Orthopedic Center
Companies covered:	Zimmer Biomet, Bone Biologics Corp., Globus Medical, Smith & Nephew Inc., Stryker, ATEC Spine, Inc., XTANT MEDICAL, Johnson & Johnson Services, Inc., Exactech, Inc., Integra LifeSciences, Medtronic, NuVasive, Inc., Orthofix US LLC., SeaSpine, ChitogenX Inc., Spine Wave, Inc., Molecular Matrix, Inc., Isto Biologics, Baxter, Locate Bio Limited, Cerapedics, Ossifix Orthopedics, and Aziyo
Growth Drivers:	Increasing adoption of inorganic strategies such as product launches by key market players
Restraints & Challenges:	Increasing number of product recalls by regulatory authorities such as the U.S. Food and Drug Administration

Figure 2. Global Orthobiologics Market Value (US$ Million), by Region, 2022

Global Orthobiologics Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a negative impact on the global orthobiologics market. For instance, in Feburary 2021, according to the data published in National Center for Biotechnology Information, rate of infection gradually increased after the orthopedic procedures, organ donation and transplantation. As living donors received pre-operative screening by PCR, and allograft bone from COVID-19-negative donors was cryopreserved as transplantable tissues. The virus can be transmitted by asymptomatic patients, and that this route may have facilitated the spread of COVID-19.

Global Orthobiologics Market: Key Developments

Increasing adoption of inorganic growth strategies such as product launches by key market players is expected to drive the global orthobiologics market growth over the forecast period. For instance, in July 2021, Orthofix US LLC., a medical device company, announced that they had launched a fiberFUSE Strip, an advanced demineralized fiber bone-graft solution containing cancellous bone which is formulated as a convenient preformed bone-graft strip to enable optimized application for posterior cervical, posterior lumbar and degenerative spinal procedures.

Global Orthobiologics Market: Restraint

Increasing number of product recalls by regulatory authorities such as the U.S. Food and Drug Administration is expected to hinder the market growth over the forecast period. For instance, in June 2021, the U.S. Food and Drug Administration recalled a FiberCel Fiber Viable Bone Matrix, a bone repair product made from human tissue that is used in various orthopedic and spinal procedures. The product was manufactured by Aziyo, a biotechnology company. The device was recalled due to the post surgical infections in patients treated with FiberCel.

Global Orthobiologics Market - Key Players

Major players operating in the global orthobiologics market include Zimmer Biomet, Bone Biologics Corp., Globus Medical, Smith & Nephew Inc., Stryker, ATEC Spine, Inc., XTANT MEDICAL, Johnson & Johnson Services, Inc., Exactech, Inc., Integra LifeSciences, Medtronic, NuVasive, Inc., Orthofix US LLC., SeaSpine, ChitogenX Inc., Spine Wave, Inc., Molecular Matrix, Inc., Isto Biologics, Baxter, Locate Bio Limited, Cerapedics, Ossifix Orthopedics, and Aziyo

Frequently Asked Questions

The global orthobiologics market is estimated to be valued at US$ 6,515.2 million in 2022 and is expected to exhibit a CAGR of 5.9% between 2022 and 2030.

Factors such as increasing adoption of inorganic growth strategies such as product launches by key market players are expected to drive the market.

Bone allograft is the leading product type segment in the market

Increasing number of product recalls by regulatory authorities such as the U.S. Food and Drug Administration are the major factors hampering the market

Major players operating in the market include Zimmer Biomet, Bone Biologics Corp., Globus Medical, Smith & Nephew Inc., Stryker, ATEC Spine, Inc., XTANT MEDICAL, Johnson & Johnson Services, Inc., Exactech, Inc., Integra LifeSciences, Medtronic, NuVasive, Inc., Orthofix US LLC., SeaSpine, ChitogenX Inc., Spine Wave, Inc., Molecular Matrix, Inc., Isto Biologics, Baxter, Locate Bio Limited, Cerapedics, Ossifix Orthopedics, and Aziyo